Kisspeptin-10 Dosage: Doses Studied, Units and Chart
What doses of Kisspeptin-10 have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 9 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- mean elimination half-life 1.3-2.2 hours
- subcutaneous (analog MVT-602), in people · Fertility and sterility 2024, PMID 37925096
- Vial sizes sold
- 5 mg, 10 mg
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 1.25-10.0 nmol/kg/h acute; 150 nmol/h daily 8 h for 12 days | daily 8 h on, 16 h off · subcutaneous infusion (kisspeptin-10) · 12 days | Human RCTn = 15 | European journal of endocrinology 2026, PMID 42549827 |
| 0.1 to 3.0 ug MVT-602 | single dose · subcutaneous | Human RCT | Fertility and sterility 2024, PMID 37925096 |
| 1 nmol/kg/h kisspeptin-54 | intravenous infusion · 75 minutes | Human RCTn = 40 | JAMA network open 2022, PMID 36287566 |
| 6.4 nmol/kg (kisspeptin-54) | twice daily · subcutaneous · 7 days | Human controlled trialn = 5 | Clinical endocrinology 2014, PMID 24863252 |
| iv bolus 0.01-3.0 ug/kg; infusion 1.5-4 ug/kg/h | intravenous (kisspeptin-10) · infusion up to 22.5 h | Human controlled trial | The Journal of clinical endocrinology and metabolism 2011, PMID 21632807 |
| 6.4 nmol/kg (kisspeptin-54) | twice daily · subcutaneous · 2 weeks | Human RCT | The Journal of clinical endocrinology and metabolism 2009, PMID 19820030 |
| 0.2-6.4 nmol/kg (kisspeptin-54) | subcutaneous bolus | Human controlled trial | The Journal of clinical endocrinology and metabolism 2007, PMID 17635940 |
| 1.6 to 12.8 nmol/kg (kisspeptin-54) | single injection · subcutaneous | Human uncontrolled trialn = 53 | The Journal of clinical investigation 2014, PMID 25036713 |
| 20 nmol/rat/day kisspeptin-10 | 7 days | Animal · rat (not a human result)n = 24 | Cell biochemistry and function 2010, PMID 20517893 |
Dose to syringe units
For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.
- 100 mcg
- 2 u
- 250 mcg
- 5 u
- 500 mcg
- 10 u
- 750 mcg
- 15 u
- 1000 mcg
- 20 u
Before anyone considers it
- Kisspeptin-10 is Not FDA approved · research chemical; research-chemical versions are not the approved drug.
- Compounded and research-chemical versions are not the approved product and are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Common questions
How many units is 500 mcg of Kisspeptin-10?
It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 500 mcg is 10 units on a U-100 syringe. Use the calculator for other mixes.
Is Kisspeptin-10 FDA approved?
Kisspeptin-10 is Not FDA approved · research chemical. Products sold as research chemicals are not the approved drug and are not checked by the FDA.
More on Kisspeptin-10
Side effectsWhat labels and studies report, and what is unknown.CalculatorVial, water and dose to syringe units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.For testosteroneWhat research says about Kisspeptin-10 for testosterone.For menopauseWhat research says about Kisspeptin-10 for menopause.
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
- 4Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026
- 5Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.JAMA network open · 2022PMID 36287566Accessed 2 Oct 2026
- 6Acute and chronic effects of kisspeptin-54 administration on GH, prolactin and TSH secretion in healthy women.Clinical endocrinology · 2014PMID 24863252Accessed 2 Oct 2026
- 7Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.The Journal of clinical endocrinology and metabolism · 2011PMID 21632807Accessed 2 Oct 2026
- 8Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.The Journal of clinical endocrinology and metabolism · 2009PMID 19820030Accessed 2 Oct 2026
- 9Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women.The Journal of clinical endocrinology and metabolism · 2007PMID 17635940Accessed 2 Oct 2026
- 10Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.The Journal of clinical investigation · 2014PMID 25036713Accessed 2 Oct 2026
- 11Direct and indirect effects of kisspeptin on liver oxidant and antioxidant systems in young male rats.Cell biochemistry and function · 2010PMID 20517893Accessed 2 Oct 2026
Found an error? Report a correction.